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Abstract Sphingolipids are bioeffector molecules that
control various aspects of cell growth, proliferation,
apoptosis, and drug resistance. Ceramides, the central
molecule of sphingolipid metabolism, are inducer of
apoptosis and inhibitors of proliferation. Sphingosine-1-
phosphate (S1P) and glucosyleceramide, converted from
ceramides by sphingosine kinase-1 (SK-1) and glucosyle-
ceramide synthase (GCS) enzymes, respectively, inhibit
apoptosis and develop resistance to chemotherapeutic
drugs. In this study, we examined the therapeutic potentials
of bioactive sphingolipids in chronic myeloid leukemia
(CML) alone and in combination with dasatinib in addition
to investigate the roles of ceramide-metabolizing genes in
dasatinib-induced apoptosis. Cytotoxic effects of dasatinib,
C8:ceramide, PDMP, and SK-1 inhibitor were determined by
XTT cell proliferation assay. Changes in caspase-3 enzyme
activity and mitochondrial membrane potential (MMP) were
measured using caspase-3 colorimetric assay and JC-1 MMP
detection kit. Expression levels of ceramide-metabolizing
genes were examined by qRT-PCR. Application of ceramide
analogs and inhibitors of ceramide clearance genes decreased
cell proliferation and induced apoptosis. Targeting bioactive
sphingolipids towards generation/accumulation of ceramides
increased apoptotic effects of dasatinib, synergistically. It
was shown for the first time that dasatinib induces apoptosis
through downregulating expression levels of antiapoptotic
SK-1 but not GCS, and upregulating expression levels of
ceramide synthase (CerS) genes, especially CerS1, in K562
cells. On the other hand, dasatinib downregulates expression
levels of both GCS and SK-1 and upregulate apoptotic
CerS2, −5 and −6 genes in Meg-01 cells. Increasing
endogenous ceramide levels and decreasing prosurvival
lipids, S1P, and GC, can open the way of more effective
treatment of CML.
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Introduction
Chronic myeloid leukemia is a hematopoetic stem cell
disorder characterized by the presence of constitutively
active breakpoint cluster region (BCR)/Abelson (ABL)
oncoprotein [1]. BCR/ABL oncoprotein results from a
reciprocal translocation of a section of human chromosome
9 that contains the ABL kinase domain and a specific BCR
on chromosome 22 [2, 3]. BCR/ABL oncoprotein regulates
many signaling pathways involved in cell growth and
proliferation, apoptosis, and differentiation [4]. It was
shown by different studies that expression of BCR/ABL
alone is enough to interpret chronic myeloid leukemia
(CML) [5–7]. Development and application of imatinib that
targets BCR/ABL oncoprotein is an important milestone for
the treatment of (CML). Imatinib binds to adenosine
triphosphate (ATP)-binding site of BCR/ABL and inhibits
phosphorylation of BCR/ABL targets that prevent leuke-
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mogenesis [8]. But, although very high hematological and
cytogenetical responses were obtained in response to
imatinib in the beginning, drug resistance was the major
drawback in imatinib-based protocols [9].
Dasatinib, is a multikinase inhibitor that inhibits the
activity of BCR/ABL and SRC kinases including SRC,
LCK, YES, and FYN in addition to c-KIT and PDGFR-
alpha and beta [10]. It acts as a competitive inhibitor at the
ATP-binding site of BCR/ABL, preventing tyrosine phos-
phorylation of the substrate molecule and downstream
signaling, causing growth arrest and apoptosis [11]. Dasati-
nib demonstrated significant activity against the mutations
on its binding site including the ones causing poor prognosis
in imatinib treatment. Dasatinib is used for the treatment of
BCR-ABL-positive CML, resistant or intolerant to imatinib
patients while it is also approved for Philadelphia chromo-
some (Ph) positive acute lymphoblastic leukemia patients
[12]. Dasatinib also demonstrated antitumoral activities on
solid tumors such as prostate, breast, lung or head, and neck
cancers [13–16].
Bioactive sphingolipids ceramide, sphingosine 1-phophate
(S1P), sphingosine, and glucosylceramide (GlcCer) are
involved in initiation and progression of cancer. They
regulate cell growth, cell proliferation, apoptosis, senes-
cence, and drug resistance [17, 18]. Ceramides are
synthesized either de novo by ceramide synthase genes
(CerS1-6) or by breakdown of sphingomyelin by sphin-
gomyelinase enzyme [19]. Different length of ceramides
were synthesized by different CerS genes [20]. While
CerS1 is responsible for synthesis of C18-ceramide [21],
CerS2 and CerS4 increase the levels of C24-ceramides
and C22-ceramides, respectively [22, 23]. C14-ceramides
and C16-ceramides were sythesised by CerS5 and CerS6
genes [24, 25]. Ceramides act as strong antitumoral
molecules supressing cell growth and proliferation and
inducing apoptosis and differentiation [26]. On the other
hand, GlcCer and S1P molecules converted from ceram-
ide by glucosylceramide synthase (GCS) and sphingosine
kinase-1 (SK-1) enzymes act as strong antiapoptotic
molecules inducing cell growth and proliferation and
inhibiting apoptosis and differentiation [27, 28]. Thus, the
balance between ceramide/GlcCer or ceramide/S1P signif-
icantly affects the fate of the cell to die or to survive. It was
also shown that intracellular concentrations of ceramides
are increased in response to stress conditions. But in
cancerous tissues and cells and in more agressive resistant
cell expressions, levels of GCS and SK-1 increases
significantly [26–28].
In the present study, we examined the roles of ceramide-
metabolizing genes in apoptosis in response to dasatinib in
Ph positive (CML) cells. We also tried to increase apoptotic
effects of dasatinib on CML cells by targeting bioactive
sphingolipids.
Materials and methods
Reagents
Dasatinib was obtained from BMS, USA. A 10-mM stock
solution was prepared with DMSO and stored at −20°C.
C8:ceramide, N-(2-hydroxy-1-(4-morpholinylmethyl)-2-
phenylethyl)-decanamide, hydrochloride (PDMP), and
SK-1 inhibitor were obtained from Cayman Chemicals,
USA, dissolved in DMSO and stored at −20°C. The final
concentration of DMSO did not exceed more than 0.1% in
culture. Primers were obtained from Eurofins, Germany.
Cell lines and culture conditions
K562 and Meg-01 human CML cells were obtained from the
German Collection of Microorganisms and Cell Cultures
(Germany). The cells were cultured in RPMI-1640 growth
medium containing 10% fetal bovine serum and 1% penicil-
lin–streptomycin (Invitrogen, USA) at 37°C in 5% CO2.
Measurement of cell growth by XTT
Antiproliferative effects of dasatinib, C8:ceramide, SK-1
inhibitor, and PDMP were determined by XTT cell prolif-
eration assay as described previously [29]. Briefly, 96-well
plates were seeded with 2×104 cells/well containing 200 μl
of the growth medium in the absence or presence of
increasing concentrations of the agents. The cells were
incubated at 37°C in 5% CO2 for 72 h. Then, they were
treated with 40-μl XTT for 4 h at CO2 incubator. After that,
the plates were read at 490 nm by Elisa reader (Thermo
Electron Corporation Multiskan Spectrum, Finland). Finally,
IC50 values of dasatinib and C8:ceramide, and IC10 values
of PDMP and SK-1 inhibitor were calculated from cell
proliferation plots. We combined increasing concentrations
of dasatinib with IC10 values of PDMP and SK-1 inhibitor
since we have previously shown that IC10 values of these
chemicals are enough to inhibit the enzyme activities and
provide accumulation of ceramides in the cells [9]. In
parallel experiments, we combined IC50 value of C8:
ceramide with increasing concentrations of dasatinib since
ceramide analogs trigger induction of generation of apoptotic
ceramides at IC50 value [30]. The magic behind these
experiments was to determine possible synergistic antiproli-
ferative effects dasatinib on K562 and Meg-01 cells in which
intracellular ceramide concentrations were increased.
Isobologram analysis for median dose effect
We used the CalcuSyn for Windows computer program
(CalcuSyn software, Biosoft, Cambridge, UK) for isobolo-
gram analysis [31]. We studied the isobologram analysis of
1266 Ann Hematol (2011) 90:1265–1275
dasatinib with C8:ceramide, PDMP, and SK-1 inhibitor
using the computer software. Experimental data points
represented by dots located below, on, or above the line,
indicate synergism, additivity, and antagonism, respective-
ly. The CI is an analysis of the combined effects of two
drugs using a median effect plot analysis. A CI value <1
indicates a synergistic effect (0.1–0.5 strong synergism;
<0.1 very strong synergism); a CI value of 1 indicates
additive effect; and a CI value >1 an antagonistic effect
(3.3–10 strong antagonism; >10 very strong antagonism).
Measurement of changes in caspase-3 enzyme activity
Changes in caspase-3 enzyme activity in response to
applied anyone of these chemical agents were assessed by
caspase-3 colorimetric assay kit (R&D Systems, USA) as
described previously [32]. The cells were treated with C8:
ceramide, PDMP, or SK-1 inhibitor itself and in combina-
tion with dasatinib for 72 h. Untreated cells were used as
control group. The cells were collected by centrifugation at
1,000 rpm for 10 min, and treated with 100 μl of cold lysis
buffer (1X) to obtain cell lysate. After incubating the cell
lysates on ice for 10 min, they were centrifuged at
14,000 rpm for 1 min. Then, the supernatants were
transferred to new microcentrifuge tubes. In order to
measure caspase-3 enzyme activity, reaction mixture in-
cluding 20 μl of assay buffer (5X), 25 μl of sample, 50 μl
of sterilized water, and 5 μl of caspase-3 colorimetric
substrate was prepared in 96-well plates and incubated for
2 h at 37°C. The samples were read under 405 nm
wavelengths by Elisa reader (Thermo Electron Corporation
Multiskan Spectrum, Finland). After measuring protein
concentrations by Bradford assay, enzyme activity levels
were normalized to protein concentrations.
Detection of the loss of mitochondrial membrane potential
(MMP)
APO LOGIX JC-1 Assay Kit (Cell Technology, USA) was
used to measure the changes in mitochondrial membrane
potential in K562 and Meg-01 cells as described previously
[32]. Shortly, the cells that had been induced to apoptosis
were collected by centrifugation at 1,000 rpm for 10 min.
Supernatants were removed, and 500 μl of JC-1 dye (1%)
was added onto the pellets. After incubation of cells for
15 min at 37°C in 5% CO2, they were centrifuged at
1,000 rpm for 5 min. Then, 2 ml of assay buffer was added
onto the pellets, and they were centrifuged for 5 min at
1,000 rpm. All the pellets were resuspended with 500 μl
assay buffer, and 150 μl from each of them was added into
black 96-well plate for a triplet measurement. The aggre-
gate red form has absorption/emission maxima of 585/
590 nm, and the green monomeric form has absorption/
emission maxima of 510/527 nm. The plate was read in
A
C
B
Meg-01 
Meg-01 
Meg-01 
Fig. 1 Effects of ceramide analogs and inhibitors of ceramide clearence
enzymes on proliferation of Meg-01 cells. Antiproliferative effects of C8:
ceramide (a), PDMP (b), and SK-1 inhibitor (c) on CML cells were
determined by the XTT cell proliferation test in a 72-h culture. The XTT
assays were performed using triplicate samples in at least three
independent experiments. The error bars represent the standard deviation
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these wavelengths by fluorescence Elisa reader (Thermo
Varioskan Spectrum, Finland). Finally, green/red (510/585)
values were calculated to determine the changes in MMP.
Total RNA isolation and quantitative reverse transcriptase-
PCR The involvement of CerS1-6 and ceramide clearance
genes (SK-1 and GCS) in dasatinib-induced apoptosis was
investigated by examining the expression levels of these
genes in response to dasatinib in K562 and Meg-01 cells. To
achieve this aim, the cells were incubated in the absence and
presence of increasing concentrations of dasatinib, and total
cellular RNAs were isolated by using RNA Isolation Kit
(Macherey-Nagel, USA). The amount and quality of RNAs
were measured by Nanodrop Photospectrometer (NanoDrop
1000 THERMO, USA). The mRNAs from total RNA
population were reverse transcribed into cDNA by using
reverse transcriptase enzyme (Moroney Murine Leukemia
Virus Reverse Transcriptase, Fermentas, USA). After 50 min
incubation at 42°C, the reactions were stopped at 95°C for
5 min. The resulting total cDNA was used in qPCR to
measure the mRNA levels of CerS1-6, SK-1, and GCS using
Roche LightCycler® 480 Real-Time PCR System (Roche,
USA). The mRNA levels of β actin were used as internal
positive control. The primer sequences were as follows:
CerS1-F (5′-CACTGCGCGCCTCTTTCG-3′);
CerS1-R (5′-ATTGTGGTACCGGAAGGCG-3′);
CerS2-F (5′-GCTGGAGATTCACATTTTAC-3′,);
CerS2-R (5′-GAAGACGATGAAGATGTTGT-3′);
CerS4-F (5′-GTTTCAACGAGTGGTTTTG-3′);
CerS4-R (5′-TGAATCTCTCAAAGGCAAG-3′);
CerS5-F (5′-ATCTTCTTCGTGAGGCTG-3′);
CerS5-R (5′-ATGTCCCAGAACCAAGGT-3′);
CerS6-F (5′-ATCAGGAGAAGCCAAGCACG-3′);
CerS6-R (5′-AGTAGTGAAGGTCAGTTGTG-3′);
SK-1-F (5′-CCGACGAGGACTTTGTGCTAAT-3′);
SK-1-R (5′-GCCTGTCCCCCCAAAGCATAAC-3′);
GCS-F (5′-ATGACAGAAAAAGTA-3′);
GCS-R (5′-GGACACCCCTGAGTG-3′);
and β-actin-F (5′-CAGAGCAAGAGAGGCATCCT-
3′); and
β-actin-R (5′-TTGAAGGTCTCAAACATGAT-3′).
Results
C8:ceramide, PDMP, and SK-1 inhibitor decreased
proliferation of CML cells in a dose-dependent manner
We have previously determined antiproliferative effects of
C8:ceramide (IC50; 60 μM), PDMP (IC10; 20 μM), and
SK-1 inhibitor (IC10; 7 μM) on K562 cells [33]. Increasing
intracellular generation and accumulation of ceramides
decreased proliferation of Meg-01 cells. IC50 value of
C8:ceramide was calculated and found to be 70 μM
(Fig. 1a) and IC10 values of PDMP and SK-1 inhibitor
were calculated as 50 μM (Fig. 1b) and 5 μM (Fig. 1c) for
Meg-01 cells, respectively.
Dasatinib/C8:ceramide, /PDMP, and /SK-1 inhibitor
inhibited proliferation of CML synergistically
The possible synergistic antiproliferative effects of combi-
nation of dasatinib with the ceramide analog and inhibitor
of ceramide clearance enzymes were determined by XTT
assay. IC50 concentration of C8:ceramide and IC10 con-
centrations of PDMP and SK-1 inhibitor were applied to
K562 and Meg-01 cells in combination with increasing
concentrations of dasatinib for 72 h. IC50 concentrations of
C8:ceramide were chosen based on its inhibitory effects on
proliferation while IC10 values of PDMP and SK-1
inhibitor were preferred because at these concentrations
they only inhibit enzyme activity but has no effect on
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Fig. 2 Effects of dasatinib, dasatinib/C8:ceramide/PDMP/SK-1 inhib-
itor combinations on proliferation of CML cells. Antiproliferative
effects of dasatinib alone and dasatinib in combination with C8:
ceramide, PDMP, and SK-1 inhibitor on K562 (A) and Meg-01 (B)
cells were determined by the XTT cell proliferation assay. The XTT
assays were performed using triplicate samples in at least three
independent experiments. The error bars represent the standard
deviation. Statistical significance was determined using one-way
analysis of variance, and p<0.05 was considered to be significant
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proliferation. CML cells were treated with different
concentrations of dasatinib (0.01 to 100 nM) for 72 h to
determine the effects on cell proliferation. IC50 of dasatinib
was found as 4 and 55 nM for K562 and Meg-01 cells,
respectively (Fig. 2a, b).
There were 26% and 31% decreases in cell proliferation
compared to untreated controls in response to 0.1 and 1 nM
dasatinib in K562 cells (Fig. 2a). But combinations of the
same doses of dasatinib with IC50 concentration of C8:
ceramide decreased proliferation of K562 cells by 72% and
76%, with IC10 value of PDMP of 42% and 49%, and with
IC10 value of SK-1 inhibitor of 40% and 45% as compared
to control, respectively (Fig. 2a).
Similar set of experiment was performed for Meg-01
cells. The results also demonstrated that there were
synergistic antiproliferative effects of increasing concen-
trations of dasatinib (1–500 nM) with C8:ceramide, PDMP,
and SK-1 inhibitor as compared to any agent alone and to
untreated control group (Fig. 2b).
As shown in Fig. 3a, the CI values of dasatinib in
combination with C8:ceramide, PDMP, and SK-1 inhibitor
were 0.00160, 0.26330, and 0.26330, respectively, in K562
cells. Combinations of dasatinib with C8:ceramide, PDMP,
and SK-1 inhibitor gave the CI values of 0.00258, 0.00253,
and 0.23522, respectively, in Meg-01 cells (Fig. 3b). A CI
value <1 indicates a synergistic effect (0.1–0.5 strong
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Fig. 3 Isobalogram analysis of combination of dasatinib with C8:ceramide, PDMP, and SK-1 inhibitor in K562 (a) and Meg-01 (b) cells
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synergism; <0.1 very strong synergism). The results
demonstrated that increasing intracellular concentrations
of ceramide in dasatinib applied CML cells resulted in
strong or very strong synergism.
The synergistic apoptotic effects of increased ceramide
levels in combination with dasatinib
In order to determine the possible synergistic apoptotic effects
of elevated ceramide levels in dasatinib-induced apoptosis,
K562 and Meg-01 cells were pretreated with C8:ceramide,
PDMP, and SK-1 inhibitor. The combinational effects of
dasatinib with C8:ceramide, PDMP, and SK-1 inhibitor were
examined by the loss of mitochondrial membrane potential
(Fig. 4a, b) and increases in caspase-3 enzyme activity
(Fig. 5a, b). The results showed that increasing intracellular
concentrations of ceramides by any one of these agents or
dasatinib application resulted in loss of MMP and increased
caspase-3 enzyme activity in a dose-dependent manner
compared to untreated controls to a certain extent. However,
application of dasatinib in K562 and Meg-01 cells, pretreated
with short-chain ceramides and inhibitors of ceramide
clearance enzyme, caused significant loss of MMP and
increases in caspase-3 enzyme activity in both K562
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Fig. 3 (continued)
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(Figs. 4a and 5a, respectively) and Meg-01 (Figs. 4b and 5b,
respectively) cells. Apoptotic effects of low concentrations of
dasatinib were increased by targeting ceramides. On the other
hand, the most significant increases were observed in
combination of dasatinib with C8:ceramide as compared to
others indicating that ceramide generation may be a more
effective treatment way than inhibition of ceramide clearance.
The involvement of ceramide-metabolizing genes
in dasatinib-induced apoptosis
In order to examine the role of ceramide generation and
ceramide clearance genes in dasatinib-induced apoptosis,
K562 and Meg-01 cells were exposed to increasing concen-
trations of dasatinib. Since Meg-01 cells are less sensitive to
dasatinib, they were exposed to higher concentrations of
dasatinib than K562 cells. qRT-PCR data showed that there
were significant increases in expression levels of CerS1
(350% and 530%), CerS2 (250% and 271%), CerS4 (101%
and 101%), CerS5 (160% and 190%), and CerS6 (124% and
150%) in K562 cells exposed to 0.1 and 1 nM dasatinib,
respectively (Fig. 6a), while expression levels of SK-1
decreased significantly (26%). Interestingly, expression
levels of GCS was increased in response to dasatinib. That
may result from significant generation of ceramides.
On the other hand, 10 nM dasatinib application resulted
in 40% and 84% decreases in expression levels of
antiapoptotic GCS and SK-1 genes in Meg-01 cells,
respectively (Fig. 6b). There were 275%, 129%, and
168% increases in mRNA levels of apoptotic CerS2, Cers5,
and CerS6 genes in response to 10 nM dasatinib in Meg-01
cells while expression levels of CerS1 and CerS4 decreased
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Fig. 4 Percent changes in cyto-
plasmic/mitochondrial JC-1 in
CML cells treated with combi-
nations of dasatinib with C8:
ceramide, PDMP, and SK-1
inhibitor. The results are the
means of three independent
experiments. The error bars
represent the standard devia-
tions, and when not seen, they
are smaller than the thickness of
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Ann Hematol (2011) 90:1265–1275 1271
slightly as compared to untreated controls and normilized to
beta-actin levels (Fig. 6b).
Discussion
Dasatinib is the second generation tyrosine kinase inhibitor
that can bind both inactive and active forms of BCR/ABL
[34]. Despite the fact that dasatinib is much more effective
than imatinib for the treatment of CML, resistance to
dasatinib is still the major drawback in CML treatment [35].
Therefore, increasing the sensitivity of CML cells to
dasatinib can provide an important outcome.
Alterations in metabolism of bioactive sphingolipids are
important regulators of tumor initiation, progression, and
chemoresistance. The balance between proapoptotic and
prosurvival signaling is affected by the ratio between
ceramide and sphingosine-1-phosphate or glucosylceramide.
Specific types of cancers can escape from cell death by
converting ceramide to sphingosine-1-phosphate or to
glucosyle ceramide by SK-1 and GCS enzymes, respectively
[36]. Therefore, targeting ceramide-metabolizing genes alone
and in combination with anticancer agents may be an
attractive treatment modality for various types of cancers.
In the current study, we tried to increase apoptotic effects of
dasatinib in combination with ceramide analogs and inhib-
itors of ceramide clearance enzymes.
It is very well-known that both exogenously applied C8-
ceramide, PDMP, and SK-1 inhibitors elevate endogenous
ceramide concentrations in various types of cancers [9, 30].
In this study, we documented that inhibition ofGCS and SK-1
with specific chemical inhibitors and exogenous C8:ceram-
ide application inhibited cell proliferation and induced
apoptosis in a dose-dependent manner in both K562 and
Meg-01 CML cells. We also treated K562 and Meg-01 cells
with combination of dasatinib and PDMP or SK-1 inhibitor
or C8:ceramide. All combinations induced apoptosis signif-
icantly as compared to any agent alone but the most
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they are smaller than the thick-
ness of the lines on the graphs.
Statistical significance was de-
termined using two-way analy-
sis of variance, and p<0.05 was
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significant increase in apoptosis was observed in combina-
tion of dasatinib and C8:ceramide. It was also shown
previously by our group and Senkal et al. that exogenous
ceramide analog applications increased apoptotic effects of
different anticancer agents in various types of cancers [37,
38].
Glucosyl ceramide synthase is the enzyme that transfers
glucose to ceramide. Gouaze et al. have shown that
inhibition of GCS increases sensitivity of resistant breast
cancer cells to chemotherapy[39]. It was also shown that
there is a direct relation between GCS and drug resistance.
They introduced GCS gene into sensitive MCF-7 breast
cancer cells and observed an apparently increase in the GCS
expression levels and as a result, the cells became
adriamycin and exogeneous ceramides resistant [40].
Targeting sphingosine kinase-1 is a novel approach for the
treatment of cancers. S1P is involved in tumor growth,
proliferation, metastasis, and angiogenesis. Overexpression
of SK-1 was observed in various types of tumors including
lung, intestine, kidney, breast, and ovary tumor as compared
to their normal counterpart tissues [41, 42]. SK-1 inhibitor,
safingol, alone demonstrated antiproliferative effects on
gastric, breast, neuroblastoma, lung, melanoma, prostate,
colon, and pancreas cancers [43, 44]. Schwartz et al.
demonstrated that safingol increased apoptotic effects of
mitomycin-C synergistically in gastric cancer cells.
The antiproliferative and apoptotic effects of exogenous
ceramides has been demonstrated in different human
cancer cells [37, 38]. Struckhoff et al. have shown
apoptotic effects of ceramide analogs on breast cancer
cells while some other structural ceramide analogs also
showed antiproliferative effects on adriamycin-resistant
SKBr3 and MCF-7 human breast cancer cells [45, 46].
On the other hand, dasatinib has anticancer effects not
only on CML but also on BCR/ABL negative tumors
including chronic lymphoid leukemia, acute myeloid
leukemia, prostate, lung, and non-small lung cancers
[47–50]. In addition to inhibition of BCR/ABL, dasatinib
can also target SRC family kinases, Lyn kinase, and EGFR
[47–50]. In order to understand the mechanisms of
dasatinib-induced apoptosis, we examined the expression
patterns of ceramide-metabolizing genes in CML cells
exposed to dasatinib. The qRT-PCR results revealed that
there were significant increases in expression levels of
CerS1, CerS2, CerS5, and CerS6 genes in response to
dasatinib in K562 cells in a dose-dependent manner, while
SK-1 is downregulated and slight increases were observed
in expression pattern of GCS as compared to untreated
Fig. 6 Expression levels of
ceramide generation and ceram-
ide clearence genes in response
to dasatinib K562 and Meg-01
cells. 0.1 and 1 nM dasatinib
were applied to K562 cells
while Meg-01 were exposed to
10 nM dasatinib for 72 h and
expression levels of ceramide-
metabolizing genes were deter-
mined by qRT-PCR. Expression
levels of beta actin were
detected as internal positive
controls
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controls. On the other hand, there were upregulations of
CerS2, CerS5, and CerS6 genes and downregulation in
SK1 and GCS in response to dasatinib in Meg-01 cells.
The results of qRT-PCR analyses may explain the
sensitivity of K562 cells to dasatinib as compared to
Meg-01 cells. While IC50 value of dasatinib in K562 cells
was 4 nM, it was 55 nM for Meg-01 cells. While dasatinib
downregulates expression levels of SK-1 and its application
results in significant increases in expression levels of all
CerS genes that result in increased generation and accumu-
lation of apoptotic ceramides in K562 cells (Fig. 6a).
However, in Meg-01 cells, since dasatinib application
results in slight increases and even decreases in expression
levels of ceramide-generating genes (Fig. 6b). On the other
hand, there may be some other unknown mechanisms of
dasatinib-induced apoptosis regulated differently in K562
and Meg-01 cells that results in differences in their
sensitivity to dasatinib.
As a conclusion, in agreement with each other, our data
demonstrated increasing intracellular concentrations of
ceramides by targeting bioactive sphingolipids increased
apoptotic effects of dasatinib synergistically. This approach
being supported by clinical data may provide more
effective treatment of CML patients.
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